The company was founded in 2005 to address the need for cellular analysis tools in the pharmaceutical, biotech, and research industries. Fluxion's proprietary microfluidic platform allows for precise cellular manipulation, rapid compound addition, environmental control, and software-based data acquisition. Their products, including ERASE-Seq, IsoFlux, BioFlux, and IonFlux, automate complex cell-based and cell-free assays, and are used by hundreds of labs worldwide to advance drug discovery, research new biology, and personalize therapies based on patient-specific biomarkers.